FDA Approves OLUMIANT — Eli Lilly and Company

Eli Lilly and Company’s FDA approval of the oral rheumatoid arthritis medication OLUMIANT (baricitinib) is expected to bolster the company’s market share in the competitive JAK inhibitor class, driving substantial revenue growth and expanding its presence in the high-demand immunology space.